MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Core Points - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][3] - The company will release its fourth quarter and year-end 2024 financial results on March 18, 2025, before the market opens [1] - A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update [1][2] Company Overview - MiNK Therapeutics is advancing a pipeline of both native and next-generation engineered iNKT programs [3] - The company aims to facilitate scalable and reproducible manufacturing for off-the-shelf delivery of its therapies [3] - MiNK Therapeutics is headquartered in New York, NY, and provides information relevant to investors on its website and social media channels [3]